fbpx Skip to content

Nottingham spinout IsomAb raises £7.5m for diabetic treatments

Image credit: IsomAb

University of Nottingham spinout IsomAb has raised £7.5m for its research into treatments for diabetic patients.

Founded in 2022, IsomAb is developing a process to treat those at risk of amputation due to diabetes. The startup is currently working on treatments for peripheral arterial disease (PAD), a condition where arteries in the legs and feet become blocked by fatty deposits, cutting off blood flow.

The company said that bodies with PAD can develop new blood vessels on their own, however, this self-recovery process does not occur in diabetics.

IsomAb, now backed by additional funding, is looking to carry out further studies as it prepares for clinical trials.

The funding round was led by Broadview Ventures, with additional funding coming from the MEIF Proof of Concept and Early Stage Fund, managed by Mercia Ventures.

The Midlands Engine Investment Fund is a vehicle to support startups in the Midlands, supported by the European Regional Development Fund.

“Peripheral artery disease remains a significant unmet medical need worldwide, and the development of novel treatments to alleviate ischemia could improve clinical care for millions of patients,” said Benjamin Kreitman, principal at Broadview Ventures.

“As Broadview’s investment strategy is focused on the improvement of human health in the areas of cardiovascular disease and stroke, we are delighted to accelerate this highly innovative approach.”

IsomAb previously received funding from the Bristol-based deep tech investor SCVC, which in September launched its second investment fund, worth £80m.